160431-24-3

Upstream product

• 70887-29-5 4-methoxybenzyl iodide 
• 133333-27-4 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 

Downstream Products

• 160431-26-5 [(1S,2S,4R)-1-Benzyl-4-[(S)-1-((S)-1-benzyl-2-morpholin-4-yl-2-oxo-ethylcarbamoyl)-2-methyl-propylcarbamoyl]-2-(tert-butyl-dimethyl-silanyloxy)-5-(4-methoxy-phenyl)-pentyl]-carbamic acid tert-butyl ester 
• 160431-25-4 5(S)-(Boc-amino)-4(S)-(tert-butyldimethylsilyloxy)-6-phenyl-2(R)-(p-methoxyphenylmethyl)-hexanoic acid 
• 162580-00-9 5(S)-(Boc-amino)-4(S)-hydroxy-6-phenyl-2(R)-(p-methoxyphenylmethyl)-hexanoic acid 

Relevant academic research and scientific papers

Use of compositions for combating tumour diseases

The present invention relates to the use of inhibitors of HIV aspartate proteases, such as HIV-1- or HIV-2-protease, and their salts and to prodrugs for inhibiting the growth of tumors, especially those tumors which do not respond to the inhibition of HIV

Synthesis of potent and orally active HIV-protease inhibitors

A series of potent HIV-protease inhibitors has been prepared. Several of the newly synthesized compounds showed high plasma levels after oral administration to animals. Based on the overall biological profile, CGP 61755 was chosen for further preclinical evaluation. For this compound, a 10 step synthesis potentially suitable for large scale production was developed.